# RegImmune Startup profile on Capital Atlas: https://capitalatlas.ai/startups/regimmune - Industry: Biotechnology - Headquarters: Tokyo, Japan - Website: www.regimmune.com - Total disclosed funding: $40M - Latest round: Series E (May 10, 2017) - Investors on record: 23 ## About RegImmune Corp. is a biopharmaceutical company dedicated to developing innovative therapies for immune disorders, focusing on enhancing immune response and managing conditions like graft-versus-host disease (GvHD).Founded in 2006 and headquartered in Tokyo, Japan, RegImmune Corp. specializes in therapies for immune disorders. Notable for its Series E funding in May 2017, the company raised JPY 650 million from a mix of new and returning investors, including Hiroshima Venture Capital and Mitsubishi UFJ Capital. The firm has successfully closed 7 deals to date, showcasing a strategic focus on the biopharmaceutical sector. The company has not undergone any publicly reported pivots or changes in business operations since its founding.REGiMMUNE focuses on innovative solutions for immune disorders, primarily through its core product offerings aimed at enhancing immune response and managing conditions such as graft-versus-host disease (GvHD). Their technology is designed to modulate the immune system, providing targeted therapies that address the underlying causes of immune dysregulation. The company's products are intended for healthcare providers and specialists treating patients with various immune-related conditions, thereby targeting a clientele that includes hospitals, clinics, and health systems across North America and Europe. By leveraging advanced biopharmaceutical technologies, REGiMMUNE aims to improve quality of life for patients suffering from immune disorders, offering them hope for more effective treatment options.REGiMMUNE's revenue is generated through strategic partnerships and collaborations within the biopharmaceutical sector, focusing on B2B transactions with healthcare providers and institutions. The company engages in direct sales and licensing agreements for its proprietary therapies, which are designed to address specific immune disorders. Revenue streams may include revenue from clinical trial agreements, product sales to healthcare facilities, and potential royalties from licensing arrangements. The company's flagship products, centered around immune modulation therapies, are structured to cater to a specialized market, reflecting the critical nature of the conditions they aim to treat. Specific pricing structures for these products have been established in alignment with industry standards, enabling REGiMMUNE to sustain its operations and funding for ongoing research and development.RegImmune Corp. plans to utilize its Series E funding, raised in May 2017, to advance new product developments and expand its geographical reach. The company aims to introduce new therapies for immune disorders over the next few years, targeting key markets in North America and Europe. Additionally, RegImmune is exploring opportunities to enter emerging markets in Asia by 2022, specifically focusing on partnerships that will enhance its distribution capabilities in these regions. ## Funding rounds - Series E, May 10, 2017, $5.7M — Japan Asia Investment Company, Mitsubishi UFJ Capital, SMBC Venture Capital, Miyako Capital, Iyogin Capital, Hiroshima Venture Capital, Oita Venture Capital, OKB Capital - Series D, Feb 14, 2014, $9.2M — Japan Asia Investment Company, Nippon Venture Capital, Mitsui Sumitomo Insurance Venture Capital, Mitsubishi UFJ Capital, SMBC Venture Capital, Mizuho Capital - Series C, Feb 1, 2012, $5M — Daiwa Corporate Investment, Japan Asia Investment Company, Sumitomo Mitsui Banking Corporation, SMBC Venture Capital, Shinkin Capital, Medinet Co., Ltd - Series B, May 6, 2008, $8M — Daiwa Corporate Investment, Japan Asia Investment Company, Whiz Partners, Yasuda Enterprise Development - Series B, Feb 1, 2008, $6M — Daiwa Corporate Investment, Japan Asia Investment Company, Whiz Partners, Resona Holdings, Yasuda Enterprise Development, New Business Investment Corporation, AC Ventures (Japan) - Series A, Feb 21, 2007, $4.2M — Daiwa Corporate Investment, Japan Asia Investment Company, JAFCO Group, ORIX, Yasuda Enterprise Development, New Business Investment Corporation, Mitsubishi UFJ Capital - Seed, Aug 15, 2006, $1.6M — Daiwa Corporate Investment, Ant Capital Partners, Japan Asia Investment Company ## Investors - Daiwa Corporate Investment (https://capitalatlas.ai/funds/daiwa-corporate-investment) — Seed, Series A, Series B, Series C - Ant Capital Partners (https://capitalatlas.ai/funds/ant-capital-partners) — Seed - Japan Asia Investment Company (https://capitalatlas.ai/funds/japan-asia-investment-company) — Seed, Series A, Series B, Series C, Series D, Series E - JAFCO Group (https://capitalatlas.ai/funds/jafco-group) — Series A - ORIX (https://capitalatlas.ai/funds/orix) — Series A - Yasuda Enterprise Development (https://capitalatlas.ai/funds/yasuda-enterprise-development) — Series A, Series B - New Business Investment Corporation — Series A, Series B - Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series A, Series D, Series E - Whiz Partners (https://capitalatlas.ai/funds/whiz-partners) — Series B - Resona Holdings — Series B - AC Ventures (Japan) (https://capitalatlas.ai/funds/ac-ventures-japan) — Series B - Sumitomo Mitsui Banking Corporation — Series C - SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series C, Series D, Series E - Shinkin Capital (https://capitalatlas.ai/funds/shinkin-capital) — Series C - Medinet Co., Ltd — Series C - Nippon Venture Capital (https://capitalatlas.ai/funds/nippon-venture-capital) — Series D - Mitsui Sumitomo Insurance Venture Capital (https://capitalatlas.ai/funds/mitsui-sumitomo-insurance-venture-capital) — Series D - Mizuho Capital (https://capitalatlas.ai/funds/mizuho-capital) — Series D - Miyako Capital (https://capitalatlas.ai/funds/miyako-capital) — Series E - Iyogin Capital (https://capitalatlas.ai/funds/iyogin-capital) — Series E - Hiroshima Venture Capital (https://capitalatlas.ai/funds/hiroshima-venture-capital) — Series E - Oita Venture Capital (https://capitalatlas.ai/funds/oita-venture-capital) — Series E - OKB Capital (https://capitalatlas.ai/funds/okb-capital) — Series E